A subsequent phase Ib trial (CHECKMATE-039) of the anti-PD-1 antibody, nivolumab, again showed a modest response in patients with r/r DLBCL and FL, with ORRs of 36% and 40%, respectively [90]. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.